2004
DOI: 10.1016/s0920-9964(03)00122-1
|View full text |Cite
|
Sign up to set email alerts
|

Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
36
0
3

Year Published

2004
2004
2020
2020

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 87 publications
(42 citation statements)
references
References 33 publications
3
36
0
3
Order By: Relevance
“…32) Based on existing studies on the correlation between daily living function and cognitive function, a correlation was found with executive function, 33) attention, 34) and working memory. 35) In addition, another study by the present authors showed a significant correlation between language ability and K-UPSA. 36) K-WAIS, WCST, and SCoRS were conducted as cognitive function tests in this study.…”
Section: Discussionsupporting
confidence: 59%
“…32) Based on existing studies on the correlation between daily living function and cognitive function, a correlation was found with executive function, 33) attention, 34) and working memory. 35) In addition, another study by the present authors showed a significant correlation between language ability and K-UPSA. 36) K-WAIS, WCST, and SCoRS were conducted as cognitive function tests in this study.…”
Section: Discussionsupporting
confidence: 59%
“…Cognitive impairment has major functional and symptomatic outcomes and is poorly managed using currently available antipsychotics (Fujii et al 2004;Green et al 2000). Thus, an effective therapy for cognitive deficits would be of great clinical importance.…”
Section: Introductionmentioning
confidence: 99%
“…Cognitive deficits in memory, executive function, and working memory are believed to be of major importance to the functional and symptomatic outcome (Fujii and Wylie, 2003;Moritz et al, 2000;Grawe and Levander, 2001;Green et al, 2000) as well as the quality of life (Fujii et al, 2004) of patients with schizophrenia. Being able to address some of these symptoms in a preclinical model and consequently develop drugs that better target these symptoms could lead to better outcome and better quality of life for the patients.…”
Section: Introductionmentioning
confidence: 99%